Due to reports of access challenges with the insulin glargine vial / SoloStar® (authorized biologic for Lantus), Lantus® SoloStar® / Vial will move to preferred on the NC Medicaid Preferred Drug List (PDL), effective March 24, 2023.
Both insulin glargine vial / SoloStar® and Lantus® SoloStar® / Vial will have preferred status on the PDL. Insulin glargine continues to be the most cost-effective option for NC Medicaid.
Additionally, temporary prior authorization (PA) overrides will be provided through NC Tracks for Lantus® through March 24, 2023, at which time the PDL will be updated to include Lantus® as a preferred product. This applies to NC Medicaid Direct. For NC Medicaid Managed Care health plans, please refer to the individual plan.
Both Lantus® and insulin glargine will remain preferred until DHB Pharmacy receives sufficient notice that the access issues have been adequately resolved for pharmacies.
Contact
NCTracks Call Center: 800-688-6696